Update!
S+C Group AG
Dear PS holders in S+C Group,
We are excited to share with you progress on SkyCell.
On the backbone of last year’s fundraising, SkyCell concluded an additional fundraise, of equity and debt, of $35M in Series C.
Furthermore, SkyCell’s team has grown its partnership base around the world from the Middle East to Japan.
Continued service excellence – SkyCell’s mission is to provide hardware, software, and services to eliminate the loss in the pharma supply chain. We are excited to share that SkyCell has been audited again to have less than 0.1% temperature excursions.
Finally, SkyCell is increasing its sustainability efforts, by joining the Science Based Targets initiative and committing to the scientific goals set out in the Paris Agreements.
See the full details of SkyCell’s latest achievements and news below.
With best regards,
Richard & S+C Group Team
SkyCell closes $35M in recent investment funding round
Setting the stage for new phase of growth capitalizing on surging global demand for safe, secure, and sustainable new pharma cold-chain solutions, SkyCell secured $35M in Series C funding, a combination of equity and debt financing.
The round included DisruptAD, ADQ’s venture platform, and SHUAA Capital (UAE-based asset management and investment banking firm) , as well as China based and Zurich based family offices with strategically important networks.
Richard Ettl, Co-Founder and CEO SkyCell
“This successful round of funding will enable SkyCell to further improve the experience we offer our clients, further differentiate our hardware and SaaS offerings based on their needs and become their distribution solution of choice for cold chain.”
Jassim Alseddiqi, Group CEO SHUAA Capital
“At SHUAA, we invest in pioneering and innovative companies, especially in vital sectors that have a significant impact on society, and that at the same time generate meaningful returns for our shareholders. SkyCell is one such business, using technology to transform the pharmaceutical supply chain, and we are excited about its growth potential in the coming years, given the importance of its role in designing and manufacturing advanced and safe drug containers.”
SkyCell news
SkyCell’s global airline partners
SkyCell now operates with 17 major airline partners from Europe to APAC to North America and LATAM regions, ensuring a worldwide reach to transport the shipment of life-saving medicines to patients.
Some of our recent airline partners in the last year include:
Qatar
Saudia Cargo
KLM Airfrance Martinair Cargo
Korean Air
LOT
Virgin Atlantic
Japan Airlines
All Nippon Airways
Ernst & Young reaffirms SkyCell hybrid’s high-performance
For the fourth year in a row, SkyCell’s hybrid has upheld its high-performance title with an audit proving less than 0.1% temperature excursions occur end-to-end with our shipments. This validates SkyCell’s reliability to transport vital medicines to patients throughout the global pharma supply chain.
SkyCell commits to Paris Agreement targets
SkyCell has joined the Science Based Targets initiative (SBTi). The SBTi shows us how to reduce our emissions in line with the Paris Agreement and set climate change mitigation targets that align with 1.5°C scenarios.
Through this, we not only demonstrate our commitment to the Paris Agreement, but also display our dedication to ensuring a sustainable pharma supply chain that brings medicine to all.
Quelle: Newsletter
Liest sich ja nicht so schlecht... wie gut das für Investoren und ex. ICO-Teilnehmer ist wird sich zeigen.
.
